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Methods: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and
cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year
period.
Results: LowCSF b-amyloid (Ab)42 levels predicted subsequent development of clinical AD 9 years
later. Noteworthy, one-third of individuals with pathologically low baseline Ab42 levels remained
cognitively intact during follow-up. No further decrease in Ab42 was seen in those with low levels
already at baseline.
Discussion: CSFAb42 predicts sporadic AD at least 9 years before dementia onset and has plateaued
already at this time. However, many individuals can harbor brain amyloid accumulation over a decade
without signs of cognitive deterioration, which could implicate howCSF biomarkers are used to iden-
tify preclinical AD in future interventional therapeutic trials.
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The slowly progressive nature of Alzheimer’s disease
(AD) implies a long preclinical phase before onset of cogni-
tive symptoms. Increasing evidence suggests that cerebral
accumulation of b-amyloid (Ab) can be detected 5–20 years
before dementia onset in AD, when using cerebrospinal fluid
(CSF) Ab42 or amyloid positron emission tomographynd O.H. report no disclosures. K.B. is on the advisory
nostics and for IBL International. All authors declare
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he Authors. Published by Elsevier Inc. on behalf of the Alzh
ns.org/licenses/by/4.0/).(PET) imaging [1–4]. Important evidence comes from
studies evaluating asymptomatic individuals with
autosomal dominant forms of AD [1,5]. To determine the
temporal evolution of AD biomarkers during the early
phases of sporadic AD, we need longitudinal studies with
repeated biomarker assessments over 5–15 years covering
the preclinical phases of AD. A few studies with repeated
longitudinal biomarker assessments in cognitively healthy
individuals have been published [6–8], but studies over
extended periods, of .4 years, are still lacking.
Several studies imply that CSF can identify cognitively
healthy elderly individuals that are at increased risk of sub-
sequent development of cognitive decline [9–14]. However,
the frequency of false positive cases is still unclear. To
address this, we need long-term follow-up cognitively
healthy individuals with deviant CSF biomarkers.eimer’s Association. This is an open access article under the CC BY license
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gated CSF biomarkers repeatedly over 9–10 years in individ-
uals, who all were cognitively healthy at baseline. The
cognitive performance and development of dementia were
determined during the clinical follow-up. Great care was
taken to minimize drop-out during the study.Fig. 1. Flowchart of inclusion and drop-out in the study sample. Abbrevia-
tion: CSF, cerebrospinal fluid.2. Methods
2.1. Study design
The objective of this study was to model within-person
neurodegenerative biomarker trajectories in preclinical AD
using repeated assessments of CSF biomarkers and cognitive
performance as well as to investigate the predictive ability of
CSF biomarkers to identify future development of clinical
dementia. It is a prospective, longitudinal, observational
study on initially cognitively healthy elderly volunteers re-
cruited through advertisement in year 2002 in the city of
Malm€o, Sweden [13], for the purpose to constitute a healthy
control group in dementia studies. Individuals who re-
sponded were included in the study unless they fulfilled
any of the prospectively set exclusion criteria. Baseline
exclusion criteria were (1) subjective cognitive decline, (2)
presence of mild cognitive impairment (MCI) or dementia,
(3) mini-mental state examination (MMSE) [15] score of
,27, and (4) presence of other morbidities possibly
affecting cognitive status such as major depressive episode,
ongoing alcohol abuse, and severs disorders of the central
nervous system. Treatable and reversible diseases that could
affect cognition were treated and did not lead to exclusion.
Included participants were then followed longitudinally in
approximately every third year with focus on cognitive per-
formance and CSF measurements.2.2. Subjects
In total, 62 individuals could be recruited of which 54 per-
formed baseline lumbar puncture and CSF collection. All
participants also underwent comprehensive examination
including physical, neurologic, and psychiatric evaluation,
computed tomography (CT) of the brain, and cognitive
testing at baseline. Cognitive follow-up was offered after
3, 5, and 9–10 years with renewed lumbar puncture after 5
and 9–10 years. Individuals with baseline CSF values and
clinical cognitive follow-up after 9 years (n 5 44) were
included in the main analyses of the present study (Fig. 1).
Only a handful of participants were evaluated after closer
to 10 years at the last follow-up, whereas the overwhelming
majority was evaluated after 9 years.
In the subgroup of participants whowere not available for
the 9-year follow-up visit (n 5 10, Fig. 1), medical record
was collected and antemortem cognitive follow-up perfor-
mances in the study were evaluated in nine cases. In this sub-
group, we found one individual who had developedMCI and
the rest were cognitively normal at the last observation.2.3. Cognitive evaluation
Cognitive testing included MMSE (all visits) [15], clock
drawing test (all visits) [16], cube drawing (all visits) [17],
delayed memory in Alzheimer’s disease assessment scale
cognitive subscale (ADAS-cog; baseline, follow-up years 5
and 9) [17], and a quick test (follow-up years 3, 5, and 9)
[18]. At follow-up after 9 years, Stroop test [19], trail mak-
ing test A and B [20], symbol digit modalities test [21], letter
S fluency test (phonemic fluency) [22], animal fluency test
(semantic fluency) [22], and month naming test (the task
of naming the months backward as fast as possible starting
with December) were also added. Delayed memory was
scored as number of correctly recalled words, which gives
higher scores when better delayed memory function.
Cognitive diagnosis was based on clinical evaluation by a
physician experienced in dementia disorders and was later
confirmed by a consensus group of experienced physicians.
The consensus group was blinded to biomarker values and
had only access to medical history, cognitive test results,
and CT scan results. Diagnosis criteria used in regular clin-
ical settings were applied, i.e. MCI [23], Alzheimer’s de-
mentia [24], vascular dementia [25], dementia with Lewy
body (DLB) [26], and other dementia (OD) [27]. DLB and
AD participants are studied together in this study because
E. Stomrud et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 403-411 405DLB patients often also have amyloid pathology next to their
synucleinopathy [28].
2.4. Lumbar puncture and CSF analyses
Lumbar puncture was performed in a sitting position with
CSF obtained from the L3/L4 or L4/L5 interspaces. All CSF
were collected in plastic (polypropylene) tubes, gently
mixed to avoid gradient effect. Samples were then centri-
fuged at 2000! g at 4C for 10 minutes to eliminate cells
and other insoluble material. Pending biochemical analyses
samples were immediately frozen and stored at 280C
without being thawed or refrozen.
Analysis of Ab42, total tau (T-tau), and phosphorylated
tau (P-tau) using xMAP technology (INNO-BIA AlzBio3
kit; Innogenetics, Ghent, Belgium) was performed using
the same batch of reagents for each CSF acquisition. A large
random sample of baseline and 5-year follow-up CSF was
analyzed together with 9-year follow-up CSF to assure
concordant assay values between all three analysis occa-
sions. CSF values are given in nanograms per liter.
2.5. Ethics
The study was approved by the regional ethics committee
at Lund University. All participants gave their written
informed consent at baseline and at each follow-up.
2.6. Statistical analysis
IBM SPSS statistics version 22 was used for statistical
analysis. Nonparametric tests were used because of the
low number of cases and the nonnormal (Gaussian) distribu-
tion of CSF biomarker levels. Differences between diagnosis
groups were calculated with Kruskal-Wallis test followed by
Mann-Whitney U test when applicable. Mann-Whitney U
test was used for dichotomized variables. Paired samples
were analyzed using Wilcoxon signed-rank test. Cox regres-
sion models were set for prediction of AD and DLB as well
as cognitive impairment. Baseline CSF levels and baseline
delayed word recall score were added separately to the
model with the following covariates: age, gender, and pres-
ence of apolipoprotein E (APOE) ε4 allele. Finally, a model
including CSF levels, delayed word recall, and all covariates
were created. Results are presented as hazard ratio (HR) with
the 95% confidence interval (CI). For baseline CSF levels,
standardized z-scores were used so that HR reflects change
per one standard deviation (SD). Cox regression models
were performed on all participants with baseline CSF mea-
surements and at least one cognitive follow-up (n 5 53),
thus including the individuals that died during the follow-
up period.
To estimate predictive ability, sensitivity, specificity, pos-
itive predictive value, and negative predictive value were
calculated. Because of the bimodal distribution of Ab42,
this measure was dichotomized using 192 ng/L as a cutoff
(Supplementary Fig. 1), which is the same as suggested byShaw et al. [29]. In addition, Kaplan-Meier survival curves
are used for temporal visualization of conversion to demen-
tia diagnosis. Significance level is set to P , .05.3. Results
3.1. Participants
Forty-four participants (n 5 44) were included in the
main analyses of the present study, as described in Fig. 1.
Demographics, cognitive performance, and CSF biomarker
levels are presented in Table 1. During the clinical follow-
up period in total, 12 individuals (27%) developed cognitive
impairment (Table 1).
3.2. Prediction of AD or DLB using baseline CSF
biomarkers
Individuals who developed AD or DLB during follow-up
had lower CSF Ab42 levels at baseline compared with the
cognitive stable individuals and OD individuals, with MCI
at intermediate levels (c2, 12.2; degree of freedom [df], 3;
P , .01; Supplementary Fig. 2). No differences in T-tau or
P-tau levels were seen.
Twelve cognitively healthy individuals (27%) had CSF
Ab42 levels at baseline below the cutoff of ,192 ng/L [29]
and were, hence, interpreted as having pathologic levels.
Six individuals in this group (50%) had developed AD
(n 5 5) or DLB (n 5 1) after 9 years of follow-up. In
contrast, no one with normal baseline CSF Ab42 levels had
developed AD or DLB. Thus, CSF Ab42 predicted develop-
ment of AD or DLB within 9 years with a sensitivity of
100%, specificity of 84%, positive predictive value of
50%, and negative predictive value of 100%.
Fig. 2A shows Kaplan-Meier survival curves of low base-
line CSF Ab42 levels compared with normal levels for pre-
diction of subsequent development of AD or DLB. Cox
regression model revealed that cognitively healthy individ-
uals with low baseline Ab42 levels had an increased risk of
subsequent AD or DLB with an HR of 11.9 (95% CI, 1.5–
94.2; P , .05) for each SD decrease of CSF Ab42 levels
when adjusted for age, gender, presence of APOE ε4 allele,
and baseline delayed word recall. In contrast, CSF tau and P-
tau did not predict development of AD/DLB over 9 years and
the ratios of CSFAb42/tau or Ab42/P-tau did not improve the
predictive ability compared with CSF Ab42 alone.
3.3. Prediction of MCI or dementia using baseline CSF
biomarkers
Twelve individuals (27%) developed some form of cogni-
tive impairment during the 9-year follow-up (Table 1). Of
these, eight had low CSF Ab42 at baseline (two MCI, five
AD, and one DLB) and four had normal baseline levels
(two MCI, one vascular dementia, and one other type of de-
mentia). Thus, CSFAb42 predicted cognitive impairment in
general (MCI or dementia) with a sensitivity of 67%,
Table 1
Group characteristics at baseline and at follow-up year 5 and year 9, including follow-up diagnoses
Characteristics Baseline Follow-up year 5 Follow-up year 9
Baseline demographics
Number (n) 44
Sex (F/M) 29/15
Age (y) 72 (65–78)
Education (y) 11 (9–15)
APOE ε4 (n) (homo-/heterozygous) 1/14
Follow-up time (mo) 111 (110–112)
Cognitive tests
MMSE (points) 30.0 (29.0–30.0) 29.0 (27.0–29.0) 28.0 (26.0–29.0)
AQT (s)* 62.0 (52.5–69.0)y 61.0 (53.5–74.5) 67.0 (56.5–84.0)
Delayed memory (ADAS), correct
words of 10
8.0 (7.0–9.0) 8.0 (7.0–9.0) 8.0 (6.0–9.0)
CSF biomarkers n 5 44 n 5 32 n 5 27z
Ab42 252.0 (174.5–312.0) 230.0 (180.5–292.5) 238.0 (139.0–275.0)
T-tau 67.5 (55.5–92.0) 74.0 (58.0–99.0) 79.0 (58.0–111.0)
P-tau 27.0 (21.5–43.5) 35.0 (21.0–50.0) 29.0 (22.0–41.0)
Follow-up diagnosis, n n 5 44 (53)x
Normal 32 (39)
Mild cognitive impairment 4 (5)
Alzheimer’s dementia 5 (5)
Lewy body dementia 1 (1)
Vascular dementia 1 (1)
Other dementia 1 (1)
Abbreviations: APOE, apolipoprotein E; MMSE, mini-mental state examination; AQT, a quick test; ADAS, Alzheimer’s disease assessment scale; CSF, ce-
rebrospinal fluid; Ab42, b-amyloid 42; T-tau, total tau; P-tau, phosphorylated tau.
NOTE. Median values with 25th–75th interquartile range within brackets.
*Color-form version of AQT is stated (reference value ,70 s).
yAQTwas not performed at baseline and, therefore, values from follow-up year 3 are given.
zNot all have CSF measurement from year 5, which results in 36 participants with two CSF assessments and 23 participants with all three CSF assessments.
CSF levels are given in ng/L.
xNumbers within brackets include premortem diagnosis for participants who deceased during follow-up and that were included in the Cox regression model.
E. Stomrud et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 403-411406specificity of 88%, positive predictive value of 67%, and
negative predictive value of 88%. Cox regression model re-
vealed that cognitively healthy individuals with low baseline
Ab42 levels had an increased risk of subsequent cognitive
impairment with an adjusted HR of 3.9 (95% CI, 1.8–8.4;
P , .05) for each SD decrease of CSF Ab42 (Fig. 2B).3.4. Prediction of AD or DLB using baseline cognitive
tests
No difference in baseline cognitive test results was seen
between the individuals that developed AD/DLB at follow-
up compared with those who remained cognitively stable
(P. .05). However, the group of individuals that developed
AD/DLB had significantly lower delayed memory scores
already at the 5-year follow-up compared with those in the
other groups (c2, 8.46; df, 3; P , .05). When added to the
Cox regression model, baseline delayed word recall score
(ADAS-cog item 3) contributed to predict development of
AD and DLB with HR of 2.8 (95% CI, 1.1–6.7; P , .05)
for each not correctly given word. However, this predictive
ability disappeared if CSF Ab42 levels were removed from
the model. This is in contrast to CSF Ab42 that remained
an independent predictive factor irrespective of delayed
word recall. Hence, CSFAb42 levels is the driving predictivefactor 9 years before diagnosis in this cohort, and episodic
memory only contributes if amyloid status is taken into ac-
count.3.5. Low baseline CSFAb42 levels and cognitive stability
over 9 years
Individual demographics and cognitive follow-up data,
for each of the participants with low baseline CSF Ab42
level, are specified in Table 2. Note that 4 of 12 individuals
(33%) exhibited no cognitive symptoms and performed well
on cognitive testing even after 9 years of follow-up. On the
other hand, these four individuals had higher CSF P-tau
levels at both baseline (U 5 96.0; P , .001) and at follow-
up after 9 years (U 5 41.5; P , .05) compared with the
cognitively normal individuals with normal baseline CSF
Ab42 levels.3.6. Longitudinal CSF biomarker levels over 9 years
Thirty-six of the individuals with CSF measurements at
baseline had at least one repeated CSF acquisition during
follow-up period (year 5 or year 9), of which 23 individuals
had from all three occasions (Fig. 3 and Supplementary Figs.
3 and 4). On group level, there was a decrease in CSF Ab42
Fig. 2. Kaplan-Meier curves for development of cognitive diagnosis depending on CSFAb42 status (A) Development of Alzheimer’s dementia and dementia
with Lewy bodies during follow-up in the group with low baseline CSFAb42 levels compared with the group with normal levels. (B) Development of cognitive
impairment (AD, DLB, VaD, or MCI) during follow-up in the group with low baseline CSFAb42 levels compared with the group with normal levels. n 5 44.
Abbreviations: CSF, cerebrospinal fluid; Ab42, b-amyloid 42; AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MCI, mild cognitive impairment.
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levels (T 5 329.5; P , .01) between baseline and follow-
up after 9 years, whereas CSF P-tau remained stable. Base-
line CSF Ab42 levels correlated negatively with baseline
CSF P-tau levels (rs 5 20.48, P , .001). Baseline CSF P-
tau levels also correlated negatively with CSF Ab42 levels
at follow-up (rs 5 20.61, P , .001). Moreover, baseline
CSF P-tau levels were significantly higher in the individuals
with low baseline CSFAb42 when compared with those with
normal baseline CSF Ab42 (U 5 310.0; P , .01), but not at
follow-up 9 years later.
Low baseline CSF Ab42 levels were observed in 10 of
these individuals and no further decrease over time
occurred (Fig. 3). Instead, the CSF Ab42 levels were stably
decreased in these 10 individuals during follow-up, of
which 7 individuals had developed AD/DLB or MCI at
the 9-year follow-up visit. In contrast, 5 of the remaining
26 individuals (19%) converted from normal CSF Ab42
levels at baseline to pathologic low levels during follow-
up. Compared with those with normal CSF Ab42 levels
also at follow-up, these individuals had higher CSF P-tau
levels at baseline (U 5 95.0, P , .05) as well as at
follow-up after 9 years (U 5 67.0, P , .01), whereas
follow-up cognitive test results, age, sex, APOE genotype,
and education did not differ.
Hence, significantly higher baseline and follow-up CSF
P-tau levels were observed in all cognitively stable partic-
ipants with low CSF Ab42 levels (at baseline or converters
during follow-up) compared with those cognitively stablewith consistent normal CSF Ab42 levels. Finally, we
observe that all individuals with MCI and AD/DLB
diagnoses tend to increase over time in CSF T-tau levels
even though this was not statistically significant
(Supplementary Figs. 3 and 4).4. Discussion
To our knowledge, no previous study has measured
CSF biomarkers repeatedly over an extended period dur-
ing the preclinical phases of sporadic AD, which is
needed to be able to determine the trajectories of
biomarker changes during the preclinical phase of spo-
radic AD. In the present study, the data suggest that
CSF Ab42 is decreased up to 9 years before dementia
onset and does not decrease further during this preclinical
phase, i.e. CSF Ab42 has already plateaued down to fully
decreased level 9 years before AD dementia onset.
Indeed, the current results do actually imply that the
decrease in CSF Ab42 occurs more than a decade before
onset of sporadic AD/DLB because several cases with
low CSF Ab42 at baseline did not develop MCI or demen-
tia during the 9-year follow-up and none of the individuals
that converted from normal to low Ab42 levels during
follow-up did develop MCI or AD. These data are in
agreement with data obtained from studies evaluating
CSF Ab42 levels in asymptomatic cases with autosomal
dominant AD [1,5]. The present data extend knowledge
obtained from studies showing that CSF Ab42 levels are
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[30,31]. The annual incidence rate of CSF Ab42
conversion was 2% in this study, which supports that
CSF Ab42 becomes reduced during adulthood rather than
childhood/adolescence.
The changes in CSF tau and P-tau might be more subtle
than the change in CSF Ab42 during the preclinical stages
of AD, and consequently more difficult to reliably detect
in CSF [3,32]. In the present study, development of AD/
DLB is not associated with baseline CSF tau or P-tau
levels. However, the individuals that developed AD/DLB
had a quite slow disease progression rate with relatively
low tau levels even at dementia onset. Instead, lower CSF
Ab42 levels are associated with higher CSF P-tau levels
throughout follow-up. Together, these data imply that CSF
P-tau might change as early as Ab42 in preclinical AD,
even though the changes are less pronounced compared
with those of CSF Ab42. Similar finding has recently been
observed in a study examining cases with autosomal domi-
nant AD [5].
Diagnostic methods are needed to accurately detect pre-
clinical AD to be able to recruit individuals with yet only
limited neurodegeneration for clinical trials. The increased
risk of future development of AD or DLB in cognitively
healthy elderly individuals with low CSF Ab42 levels is
in agreement with previous studies [9–12,14]. However,
despite a high negative predictive value (100%), several
individuals with low baseline CSF Ab42 levels did not
develop AD or DLB during a follow-up period of nearly
a decade. In fact, a remarkable one-third (n 5 4) of the in-
dividuals with low baseline CSF Ab42 levels remained
completely cognitive intact (Table 2). We later confirmed
pathologic amyloid load in neocortex in all these four indi-
viduals at follow-up using [18F]flutemetamol PET
(Supplementary Material). The study, therefore, highlights
the possibility for elderly individuals to harbor amyloid pa-
thology for a long period without development of cognitive
dysfunction. Our findings, hence, demonstrate the diffi-
culties of using amyloid markers, such as CSF Ab42 or am-
yloid PET, alone in the diagnostic workup of preclinical
AD. The combination with one or preferably several
markers that reflects brain dysfunction or neurodegenera-
tion has been suggested [33,34], such as with regional
brain atrophy [35,36], regional cerebral hypoperfusion
[37,38], decreased regional glucose metabolism [36,39],
or altered cortical connectivity (through resting state
functional magnetic resonance imaging) [40]. To optimize
this diagnostic workup will in the future be very important
when recruiting individuals with signs of brain amyloid
accumulation, but no cognitive symptoms or impairment,
for clinical trials evaluating new disease-modifying thera-
pies that might cause significant side-effects. The tolerance
for side-effects in such trials should be low if inclusion
criteria are used that results in recruitment of population
where up to 50% in the placebo group will be free of
AD after more than a decade. Therefore, there is an urgent
Fig. 3. Temporal development of CSF Ab42 levels for each individual divided according to follow-up cognitive diagnoses n 5 36 individuals. CSF: all
occasions5 23 individuals, baseline1 year 5 5 9 individuals, baseline1 year 95 4 individuals. Cognitive groups: (A) Normal-Normal n5 26 individuals,
(B) Normal-MCI n 5 3 individuals, (C) Normal-AD/DLB n 5 5 individuals, and (D) Normal-other dementia n 5 2 individuals. Green dotted line represents
change of mean value for each group with more than four participants. Red dotted line indicates cutoff 192 ng/L, suggested by Shaw et al [29]. Abbreviations:
CSF, cerebrospinal fluid; Ab42, b-amyloid 42; MCI, mild cognitive impairment; AD, Alzheimer’s disease; DLB, dementia with Lewy bodies.
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individuals evaluating different diagnostic algorithms
including amyloid biomarkers in combination with
different biomarkers that reflect disease stage.
There are limitations to this study. First, the number of
participants is too low for extended subgroup analyses.
Second, cognitive impairment occurs late in the follow-
up. This could indicate that the group at baseline did
not represent the entire spectrum of noncognitively
impaired individuals in the community. Third, only one
participant developed DLB, which prevents statisticalanalysis of this disease group separately. However, DLB
often presents amyloid pathology and presumably lies in
the disease spectrum between Parkinson’s disease (synu-
cleinopathy) and AD (amyloidopathy) [28]. We, therefore,
grouped AD and DLB, but the findings of this study
remain also if the DLB participant is removed from this
group. Fourth, CT was used for neuroimaging throughout
the study, mainly owing to magnetic resonance imaging
not being as accessible at the start of the study in 2002.
The study was also planned primarily as a CSF biomarker
study, in which CT is sufficient to exclude
E. Stomrud et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 403-411410contraindications for lumbar puncture and to evaluate
occurrence of clinically relevant cerebral lesions. Never-
theless, the study has invaluable strengths. We describe
within-person changes in CSF biomarkers over a decade
in healthy elderly individuals. Because a subgroup devel-
oped AD, we could also study these within-person
changes during the preclinical (asymptomatic) stages of
AD. All conversions to dementia occurred between
follow-up year 5 and year 9 and would not have been
identified with shorter follow-up. Hence, secondary end
points are replaced by primary end points (i.e. dementia
diagnosis). Finally, 44 of 54 individuals (81%) had clin-
ical follow-up evaluation, which is very high in the light
of 9 years of follow-up in an older population. With the
medical record examination of the deceased, only two in-
dividuals (4%) of the included subjects lack 9-year
follow-up. Hence, the results reflect the actual state of
this entire study population.5. Conclusions
Low CSF Ab42 levels predict development of AD at
least 9 years before dementia onset with a very high nega-
tive predictive value. Data obtained from the repeated CSF
measurements imply that CSF Ab42 levels have decreased
and reached a plateau already a decade before clinical
onset of dementia in sporadic AD. Surprisingly, many indi-
viduals can harbor brain amyloid accumulation over a
decade without any signs of cognitive deterioration, which
will clearly implicate how CSF biomarkers are used to
identify preclinical AD in future interventional therapeutic
trials.
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1. Systematic review: Traditional sources (such as
PubMed) were reviewed with focus on predicting
sporadic dementia in cognitively healthy individuals.
A handful publications have investigated these elon-
gated preclinical stages, although very few with
follow-up exceeding 5 years. Instead, current evi-
dence is mainly derived from evaluating autosomal
dominant Alzheimer’s disease (AD).
2. Interpretation: Our findings improve the understand-
ing of how cerebrospinal fluid AD-biomarkers can be
interpreted in absence of cognitive symptoms. They
align with current hypothesis that b-amyloid is an
early marker of AD but also confirm difficulties of
interpreting their predictive relevance on individual
level. This could implicate their use for identifying
preclinical AD in future therapeutic trials.
3. Future directions: The article elucidates the need for
long follow-up in preclinical AD studies. This to
clarify (1) how long individuals can harbor brain
amyloid accumulation without cognitive impact and
(2) which biomarker combination that correctly
identifies preclinical AD with impending risk of
dementia conversion.References
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